Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
Public ClinicalTrials.gov record NCT03972527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Radiation Therapy With or Without Concurrent Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving radiation therapy with or without concurrent chemotherapy.
Study identification
- NCT ID
- NCT03972527
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2022 (Actual)
- Primary completion
- Jun 26, 2024 (Actual)
- Completion
- Jul 18, 2024 (Actual)
- Last update posted
- Aug 21, 2024
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| The Oncology Institute | Long Beach | California | 90805 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| St. Elizabeth Healthcare | Edgewood | Kentucky | 41017 | — |
| Willis-Knighton Cancer Center | Shreveport | Louisiana | 71103 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 29216 | — |
| Erie County Medical Center | Buffalo | New York | 14215 | — |
| NYU Langone | New York | New York | 10016 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| MetroHealth | Cleveland | Ohio | 44109 | — |
| James Cancer Hospital at The Ohio State University | Columbus | Ohio | 43210 | — |
| Oklahoma Cancer Specialtists and Research Intstitute | Tulsa | Oklahoma | 74146 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03972527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03972527 live on ClinicalTrials.gov.